Skip to content

Merakris at SAWC 2025

Thanks for stopping to talk to us at SAWC 2025. We’re excited about the commercial applications for our Dermacyte Matrix and Dermacyte AC Matrix to advance wound healing and about the ongoing clinical trials for our MTX-001 subcutaneous injectable therapy.

Let’s stay in touch – just fill out this form and we’ll get in touch after the show.

Let’s talk after SAWC!

Your Name(Required)
Email Address(Required)

 

See and hear Merakris at SAWC

  • Visit booth #112
  • Hear Sean O’Connell, PhD present poster CS-081 on Subcutaneous Injectable Therapy Advancing Closure Success in Chronic Venous Leg Ulcers, Friday, May 2 at 7:45pm in Longhorn C
Scientist operating microscope

About Merakris

Merakris Therapeutics is a clinical-stage biotechnology company singularly focused on the research, development and commercialization of regenerative healthcare products.

Founded in 2016, Merakris builds on its years of scientific research to develop cutting-edge precision, cell-free regenerative therapies across multiple indications.

In addition to a robust pipeline including an investigational new drug, MTX-001, a subcutaneous injectable for VLU healing, we offer commercially available, cell-free wound coverings for general wound care and ophthalmic applications.

Top